Exelixis (NASDAQ:EXEL) Lowered to Neutral Rating by Bank of America
Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by equities research analysts at Bank of America from a “buy” rating to a “neutral” rating in a research note issued on Tuesday, Marketbeat reports. They currently have a $39.00 target price on the biotechnology company’s stock, up from their prior target price of $35.00. Bank of […]
More Stories
iTeos Therapeutics (NASDAQ:ITOS) Price Target Lowered to $19.00 at Wells Fargo & Company
iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) had its target price decreased by analysts at Wells Fargo & Company from...
Morgan Stanley Issues Positive Forecast for Block (NYSE:SQ) Stock Price
Block (NYSE:SQ – Free Report) had its target price raised by Morgan Stanley from $60.00 to $65.00 in a research...
Tronox Holdings PLC Enters into Term Loan Repricing Agreement
Tronox Holdings PLC, a global mining and inorganic chemicals company, announced on December 18, 2024, that its subsidiary, Tronox Finance...
Zacks Research Predicts Stronger Earnings for Curtiss-Wright
Curtiss-Wright Co. (NYSE:CW – Free Report) – Stock analysts at Zacks Research upped their FY2024 EPS estimates for Curtiss-Wright in...
**Edible Garden Reports 51% Surge in Thanksgiving Sales****
** Edible Garden AG Incorporated (NASDAQ: EDBL) has recently disclosed its preliminary financial performance for the Thanksgiving holiday period, showcasing...
FY2024 EPS Estimates for OTCMKTS:MHGU Cut by Northland Capmk
Meritage Hospitality Group Inc. (OTCMKTS:MHGU – Free Report) – Northland Capmk decreased their FY2024 earnings per share (EPS) estimates for...